Study of Raludotatug Deruxtecan for Advanced Ovarian Cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests a new drug (raludotatug deruxtecan) with or without another drug (bevacizumab) as maintenance therapy after initial chemotherapy for advanced ovarian cancer. It aims to see if this combination can help keep the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced ovarian, fallopian tube, or primary peritoneal cancer (Stage III or IV) with a high-grade serous or endometrioid subtype.
- You must have completed initial platinum-based chemotherapy and your disease must not have worsened (stable disease or better).
- You must not have had any prior systemic cancer treatment except the first-line chemotherapy for this cancer.
- You must have recovered from any major surgery before starting the study.
- You must not have any other cancer that is progressing or needs treatment within the last 3 years.
- You must not have active inflammatory bowel disease, a serious lung condition, or a bowel blockage related to your cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called raludotatug deruxtecan (with or without bevacizumab) for people with ovarian cancer that has grown despite PARP inhibitor maintenance treatment. The goal is to see if this drug can shrink tumors or slow the cancer's growth.
This study tests a new investigational drug, raludotatug deruxtecan (R-DXd), given alone or with another drug called bevacizumab, as maintenance treatment after second-line platinum-based chemotherapy for recurrent ovarian cancer. The goal is to keep the cancer from growing longer.
This trial tests whether adding trastuzumab deruxtecan to standard maintenance therapy with bevacizumab works better than bevacizumab alone for people with advanced ovarian cancer that has the HER2 protein. It is for those who have finished initial chemotherapy plus bevacizumab and are now starting maintenance treatment.
This trial compares a targeted drug called trastuzumab deruxtecan to standard treatment for ovarian, fallopian tube, or primary peritoneal cancer that has come back after previous treatment with a PARP inhibitor. The study is for patients whose tumors show a certain level of a protein called HER2 on their surface.
This study tests whether adding a new pill (INCB123667) to the usual maintenance drug bevacizumab (Avastin) can keep ovarian cancer from coming back, compared to bevacizumab alone. It is for women who have finished their first chemo and are in remission or have stable disease.
This Phase 2 study tests the drug Dato-DXd (alone or with other cancer medicines) in people with advanced solid tumors. It looks for tumor shrinkage and how safely the treatment can be given.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.